AstraZeneca: Yingfeifan combined chemotherapy approved in China as the first immunotherapy regimen for advanced biliary cancer patients
因醉鞭名马幌
发表于 2023-11-14 17:04:48
275
0
0
On November 14th, AstraZeneca announced that Infineon&Co; Reg; (English trade name: IMFINZI®, common name: Duvalizumab) has officially obtained approval from the National Drug Administration on November 7th for the combination of gemcitabine and cisplatin for first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) in adult patients. This plan is the first approved immunotherapy plan for biliary tract cancer in China.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Before the United States! What is the safety and efficacy of the world's first weekly insulin injection approved in China
- The world's first! French regulatory authorities sue NVIDIA
- Alibaba launches the first AI picture book tool in China to care for children with autism
- JD Group and Hailan Group have reached a strategic cooperation and will open the first JD Aolai offline store
- NIO's first fourth substitution power station in Beijing officially goes online
- New breakthrough in AI chips! SK Hynix, the world's first to achieve mass production of 12 layer HBM3E products, saw its stock price surge by nearly 9%
- The first new force in car manufacturing! Ideal car's one millionth complete vehicle rolled off the production line
- Mingchuang Youpin Ye Guofu: Retail industry should not compromise on prices. Going abroad should first go to Southeast Asia and then to Europe and America
- Is OpenAI's first AI assistant product for the 'next major breakthrough' or will it be released in January next year to revolutionize human-computer interaction?
- Xiaopeng Motors opens its first store in Australia
